Filing Details
- Accession Number:
- 0000899243-18-017779
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-22 18:56:18
- Reporting Period:
- 2018-06-22
- Accepted Time:
- 2018-06-22 18:56:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1731831 | Eidos Therapeutics Inc. | EIDX | Pharmaceutical Preparations (2834) | 463733671 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1742485 | Neil Kumar | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2550 San Francisco CA 94104 | Chief Executive Officer | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-06-22 | 18,826,417 | $0.00 | 18,826,417 | No | 4 | C | Indirect | See footnote |
Common Stock | Disposition | 2018-06-22 | 211,762 | $17.00 | 18,614,655 | No | 4 | F | Indirect | See footnote |
Common Stock | Acquisiton | 2018-06-22 | 1,000,000 | $17.00 | 19,614,655 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | F | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Series B Preferred Stock | Warrants | Disposition | 2018-06-22 | 332,262 | $0.00 | 332,262 | $10.83 |
Common Stock | Series B Convertible Preferred Stock | Acquisiton | 2018-06-22 | 332,262 | $0.00 | 397,385 | $0.00 |
Common Stock | Series B Convertible Preferred Stock | Disposition | 2018-06-22 | 2,909,029 | $0.00 | 3,479,198 | $0.00 |
Common Stock | Series Seed Preferred Stock | Disposition | 2018-06-22 | 12,832,123 | $0.00 | 15,347,219 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | X | Indirect | ||
2,909,029 | No | 4 | X | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
- The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
- Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.